Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy
Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy
复制标题
DOI：
10.1016/j.fertnstert.2016.12.024
复制
发表时间：
2017-03-01
影响因子：
6.7
通讯作者：
Alfaraj, Sukinah
中科院分区：
文献类型：
--
作者：
Bedaiwy, Mohamed A.;Allaire, Catherine;Alfaraj, Sukinah
子宫内膜异位症可以在手术或药物治疗后复发。实施长期药物治疗以治疗症状或预防复发。地诺孕素和促性腺激素释放激素（GnRH）类似物与激素反加疗法似乎对子宫内膜异位症相关疼痛症状的长期治疗同样有效。没有足够的证据支持一种疗法优于另一种疗法。然而，对于使用GnRH激动剂的患者，建议使用激素治疗（HT）。治疗选择取决于治疗效果、耐受性、药物成本、医生的经验和预期的患者依从性。（C）2017年由美国生殖医学学会。
Endometriosis can recur after either surgical or medical therapy. Long-term medical therapy is implemented to treat symptoms or prevent recurrence. Dienogest and gonadotropin-releasing hormone (GnRH) analogues with hormone add-back therapy seem to be equally effective for long-term treatment of pain symptoms associated with endometriosis. There is insufficient evidence to support the superiority of one therapy over the other. However, add-back hormone therapy (HT) is recommended for patients using GnRH agonists. The treatment selection depends on therapeutic effectiveness, tolerability, drug cost, the physician's experience, and expected patient compliance. (C)2017 by American Society for Reproductive Medicine.